Should you buy Adamis pharmaceuticals (ADMP) stock on options?
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
Does Adamis Pharmaceuticals stock pay a dividend?
Adamis Pharmaceuticals does not currently pay a dividend. Adamis Pharmaceuticals does not have a long track record of dividend growth. In the past three months, Adamis Pharmaceuticals insiders have not sold or bought any company stock. Only 5.90% of the stock of Adamis Pharmaceuticals is held by insiders.
Is ADMP a buy or sell?
Maxim Group is very positive about ADMP and gave it a "Buy" rating on Sep 23, 2020. The price target was set to $1.50 . Support & Resistance - Acc. volume What is stop-loss?
Is Adamis Pharmaceuticals'stock overvalued or undervalued?
Only 10.13% of the stock of Adamis Pharmaceuticals is held by institutions. Earnings for Adamis Pharmaceuticals are expected to grow in the coming year, from ($0.19) to ($0.16) per share. Adamis Pharmaceuticals has a P/B Ratio of 20.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Is ADMP stock a good buy?
The 1 analysts offering 12-month price forecasts for Adamis Pharmaceuticals Corp have a median target of 1.50, with a high estimate of 1.50 and a low estimate of 1.50. The median estimate represents a +191.32% increase from the last price of 0.51.
Why is ADMP stock dropping?
ADMP are crashing, down over 50% in morning trading after news broke that the Food and Drug Administration (FDA) sent the company a Complete Response Letter (CRL) about its New Drug Application of Epinephrine Injection USP 1:1000, 0.3mg Pre-Filled Single Dose Syringe (Epinephrine Pre-Filled Syringe).
Did Admp get FDA approval?
Adamis Pharmaceuticals has two intramuscular injection rescue products approved by the FDA, SYMJEPI, and ZIMHI. In addition, the company's COVID-19 candidate, TEMPOL, has shown incredible promise thus far.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.
Signals & Forecast
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adamis Pharmaceuticals stock.
Support, Risk & Stop-loss
The Adamis Pharmaceuticals Corporation stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Adamis Pharmaceuticals Corporation stock A Buy?
Adamis Pharmaceuticals Corporation finds support from accumulated volume at $0.61 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are negative as most recent trades are sells in Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Adamis Pharmaceuticals Corporation
In the last 100 trades there were 1.98 million shares bought and 1.09 million shares sold. The last trade was done 71 days ago by Marguglio David J. who sold 13 thousand shares. For the period there has been more stocks bought than sold among the insiders, but most of the latest transaction have been insiders selling.
Golden Star Signal
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
60 Biggest Movers From Yesterday
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.
56 Biggest Movers From Yesterday
Gainers Engine Gaming and Media, Inc. (NASDAQ: GAME) rose 51% to $4.80 in pre-market trading after the company reported Q4 2021 and FY21 revenue was higher year over year.
Transparency is our policy. Learn how it impacts everything we do
Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).
How we make money
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
How we use your personal data
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
How we approach editorial content
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
What is Adamis Pharmaceuticals?
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.
Is ZacksTrade a separate company?
Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California.
Pre-Market Trades
ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
About Pre-Market Quotes
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
